eGene's Cost Benefits Outlined in Application Note in June/July Issue of American Laboratory News Magazine
7/18/2006 11:58:05 AM
IRVINE, Calif., Jul 18, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading bioengineering company that has developed a compact and automated digital genetic analyzer, is the focus of an Application Note article in the June/July 2006 issue of American Laboratory News. In the article, the cost benefits of the Multicapillary Electrophoresis System developed by eGene are compared to traditional methods of genetic analysis.
As the article states: "the HDA-GT12 system reduces separation time from two or three hours to 10 minutes. It eliminates the labor-intensive procedures of manual sample loading, visual examination, data analysis, photo-taking and record-keeping. The system enables minimal human intervention, thus reducing the possibilities of human error." The article provides specific cost comparisons of the eGene system versus conventional gel electrophoresis of 12 samples. The total difference: with the traditional methods used, the cost was anywhere from $37.48-$67.48 for 12 samples whereas the eGene costs were significantly reduced to only $6.40 for the same 12 samples.
Equally impressive were the exact comparisons of the workflow time comparisons. Conventional agarose gel electrophoresis of 12 samples took a total of 101-191 minutes versus eGene's fast 10.2-minute effort.
"The benefits are unmistakable," said Dr. Ming Liu, chief executive officer of eGene. "When we demonstrate our system to lab workers, researchers and other scientists, they immediately see the benefits of our system."
American Laboratory News is edited for chemists and life scientists who have a professional interest in the application of modern scientific instrumentation for the practical use in laboratories. The editorial content covers the latest advances in laboratory instrumentation.
The HDA-GT12(TM) (high-performance DNA analyzer for genotyping on 12 channels) is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. eGene recently announced that it can successfully identify the DNA of the bird flu virus in as little as five minutes for 12 samples or 50 minutes for 96 samples.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
